Replies to post #258464 on NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

Back at that time. Yes, in hindsight, I think they were full of it on production capacity/capability estimations.

[Rootjim]

I believe they meant by capacity, was having a large enough building space and outsourcing suppliers to ramp up as needed.The foundation has been laid to keep up with demand. They (NWBO) have the capacity to meet the demand for DCVax-L after FDA approval. IMO

[tryn2]

Does anyone here know how many patients one suite can handle a year...??? Any factual links as opposed to opinion...???

[GoodGuyBill]

AVII77, No one said NWBO, with it's manufacturing facilities at that time could manufacture DCVax-L for 5000 patients. The statement was,

There is a large amount of expansion space, which is already planned for build- -out in stages to allow for scale -up of production capacity in a modular fashion as the need increases for commercialization. This would allow Cognate's current facility to increase to a total capacity of some 5,000 patients per year

Now LP did say:

The current manufacturing facilities are sufficient to produce DCVax for at least several thousand patients per year.

https://www.sec.gov/Archives/edgar/data/1072379/000114420413020507/v338517_10k.htm

Cognate’s manufacturing facility for clinical-grade cell products is located in Memphis, Tennessee, near the airport. Memphis is a worldwide air shipping hub for both Federal Express and UPS. Cognate's facility is approximately 35,000 square feet and contains substantial expansion space in addition to the portions currently built out and in use. The current manufacturing facilities are sufficient to produce DCVax for at least several thousand patients per year — an amount well in excess of what is needed for the late stage clinical trial under way. There is a large amount of expansion space, which is already planned for build- -out in stages to allow for scale -up of production capacity in a modular fashion as the need increases for commercialization. This would allow Cognate's current facility to increase to a total capacity of some 5,000 patients per year. In addition, the manufacturing arrangements with Fraunhofer in Germany and Kings College London in the United Kingdom provide further manufacturing capacity and flexibility. As a comparison, Dendreon commercially launched its Provenge dendritic cell vaccine for prostate cancer with initial manufacturing capacity for only 2,000 patients per year for a cancer that occurs in at least 100,000 new cases per year In the U.S. alone.